Evolution of cerebrospinal fluid total α-synuclein in Parkinson's disease

Marthe Gurine Førland; Annika Öhrfelt; Ingvild Dalen; Ole-Bjørn Tysnes; Kaj Blennow; Henrik Zetterberg; Kenn Freddy Pedersen; Guido Alves; Johannes Lange

doi:10.1016/j.parkreldis.2018.01.018

Evolution of cerebrospinal fluid total α-synuclein in Parkinson's disease

Parkinsonism Relat Disord. 2018 Apr:49:4-8. doi: 10.1016/j.parkreldis.2018.01.018. Epub 2018 Jan 31.

Authors

Marthe Gurine Førland¹, Annika Öhrfelt², Ingvild Dalen³, Ole-Bjørn Tysnes⁴, Kaj Blennow⁵, Henrik Zetterberg⁶, Kenn Freddy Pedersen⁷, Guido Alves⁸, Johannes Lange⁹

Affiliations

¹ The Norwegian Centre for Movement Disorders, Stavanger University Hospital, PO Box 8100, 4068, Stavanger, Norway.
² Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Sahlgrenska University Hospital at Mölndal, University of Gothenburg, 43180, Mölndal, Sweden.
³ Section of Biostatistics, Department of Research, Stavanger University Hospital, PO Box 8100, 4068, Stavanger, Norway.
⁴ Department of Neurology, Haukeland University Hospital, PO Box 1400, 5021, Bergen, Norway; Institute for Clinical Medicine, University of Bergen, PO Box 1400, 5021, Bergen, Norway.
⁵ Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Sahlgrenska University Hospital at Mölndal, University of Gothenburg, 43180, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, 43180, Mölndal, Sweden.
⁶ Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Sahlgrenska University Hospital at Mölndal, University of Gothenburg, 43180, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, 43180, Mölndal, Sweden; Department of Molecular Neuroscience, UCL Institute of Neurology, University College London, Gower Street, WC1E 6BT, London, UK; UK Dementia Research Institute, Box 16, National Hospital for Neurology and Neurosurgery, Queen Square, WC1N 3BG, London, UK.
⁷ The Norwegian Centre for Movement Disorders, Stavanger University Hospital, PO Box 8100, 4068, Stavanger, Norway; Department of Neurology, Stavanger University Hospital, PO Box 8100, 4068, Stavanger, Norway.
⁸ The Norwegian Centre for Movement Disorders, Stavanger University Hospital, PO Box 8100, 4068, Stavanger, Norway; Department of Neurology, Stavanger University Hospital, PO Box 8100, 4068, Stavanger, Norway; Department of Mathematics and Natural Sciences, University of Stavanger, Stavanger, Norway.
⁹ The Norwegian Centre for Movement Disorders, Stavanger University Hospital, PO Box 8100, 4068, Stavanger, Norway. Electronic address: [email protected].

PMID: 29409704
DOI: 10.1016/j.parkreldis.2018.01.018

Abstract

Introduction: Cerebrospinal fluid (CSF) total α-synuclein is considered a potential biomarker for Parkinson's disease (PD), but little is known about the evolution of this marker during the course of the disease. Our objective was to investigate whether CSF total α-synuclein concentrations change over time and are associated with motor and cognitive function in PD.

Methods: CSF total α-synuclein concentrations were quantified in 56 longitudinally followed PD patients, 27 of whom provided CSF repeatedly 2 and/or 4 years later. Another 18 subjects were included as controls. The samples were analyzed using two independent, validated ELISA methods: our recently developed and validated in-house ELISA and a commercial kit from BioLegend.

Results: CSF total α-synuclein levels did not distinguish PD patients from controls, displayed no substantial changes during a period of up to 4 years, and did not predict subsequent motor or cognitive decline. These findings were consistent for both analytical methods.

Conclusion: Our findings do not support the clinical utility of total α-synuclein as a single diagnostic or prognostic biomarker in PD.

Keywords: Biomarker; Cerebrospinal fluid; Longitudinal measurements; Parkinson's disease; α-synuclein.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Aged
Biomarkers / cerebrospinal fluid
Cognitive Dysfunction / cerebrospinal fluid*
Cognitive Dysfunction / etiology
Cognitive Dysfunction / physiopathology
Disease Progression*
Female
Follow-Up Studies
Humans
Male
Middle Aged
Parkinson Disease / cerebrospinal fluid*
Parkinson Disease / complications
Parkinson Disease / physiopathology
alpha-Synuclein / cerebrospinal fluid*

Substances

Biomarkers
alpha-Synuclein